{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:30:31Z","timestamp":1791725431722,"version":"4.3.4"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Managing West syndrome (WS) becomes arduous in regions where access to adrenocorticotropic hormone and vigabatrin is limited, particularly in developing nations. This study aimed to evaluate the efficacy of very high-dose oral prednisolone in children diagnosed with WS. Children aged 2\u201336\u2009months presenting with WS were consecutively enrolled and given oral prednisolone @ 8\u2009mg\/kg\/day (maximum 40\u2009mg) for two weeks followed by tapering doses over the subsequent two weeks. Weekly follow-ups were conducted until therapy completion, followed by bi-weekly assessments for three months. Responses (primary outcome) were assessed at two weeks and categorized as complete (spasm-free), partial (&amp;gt;25% reduction), or no response (&amp;lt;25% reduction). Neurodevelopmental outcomes, clinical\u2013radiological profiles, safety, and therapy response predictors were also assessed. Of the 80 children, 73.7% exhibited a complete response, while 21.2% and 5% showed partial and no response, respectively. The mean age at spasm onset and presentation was 4.98\u2009\u00b1\u20094.37\u2009months and 14.36\u2009\u00b1\u20097.13\u2009months, respectively. Perinatal brain injury accounted for 87.5% of WS cases. Adverse effects, including weight gain (8.7%), irritability, hypertension, and disturbed sleep (3.7% each), were noted. Spasm cessation at 2\u2009weeks, appropriate gestational age, and the absence of other seizure types were predictive of a favorable response. High-dose oral prednisolone emerges as an effective, low-cost, and safer first-line treatment option with minimal adverse effects in the Uttar Pradesh region in India, and this would likely be true in other resource-limited settings.<\/jats:p>","DOI":"10.1093\/tropej\/fmaf005","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:27:45Z","timestamp":1738153665000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the efficacy of very high-dose oral prednisolone in West syndrome: in Uttar Pradesh, India, a resource-limited setting"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-2372","authenticated-orcid":false,"given":"Chandra","family":"Prabha","sequence":"first","affiliation":[{"name":"Department of Pediatrics, King George's Medical University , Lucknow, Uttar Pradesh, 226003,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Kanta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, King George's Medical University , Lucknow, Uttar Pradesh, 226003,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-1494","authenticated-orcid":false,"given":"Arpita","family":"Bhriguvanshi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, King George's Medical University , Lucknow, Uttar Pradesh, 226003,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5309-4336","authenticated-orcid":false,"given":"Sanjeev Kumar","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, King George's Medical University , Lucknow, Uttar Pradesh, 226003,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"2025030420305202000_fmaf005-B1","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.ebr.2020.100397","article-title":"Infantile spasms: etiology, lead time and treatment response in a resource-limited setting","volume":"14","author":"Surana","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"2025030420305202000_fmaf005-B2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2018.06.011","article-title":"Treating infantile spasms with high-dose oral corticosteroids: a retrospective review of 87 children","volume":"87","author":"Gonzalez-Giraldo","year":"2018","journal-title":"Pediatr Neurol"},{"key":"2025030420305202000_fmaf005-B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/epi.12460","article-title":"Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone","volume":"55","author":"Hussain","year":"2014","journal-title":"Epilepsia"},{"key":"2025030420305202000_fmaf005-B4","volume-title":"DST Manual + Know Your Child\u2019s Intelligence and How to Improve It","author":"Bharath Raj","year":"1983"},{"key":"2025030420305202000_fmaf005-B5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"2025030420305202000_fmaf005-B6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.eplepsyres.2014.06.019","article-title":"High dose (4 mg\/kg\/day) versus usual dose (2 mg\/kg\/day) oral prednisolone for treatment of infantile spasms: an open-label, randomized controlled trial","volume":"108","author":"Chellamuthu","year":"2014","journal-title":"Epilepsy Res"},{"key":"2025030420305202000_fmaf005-B7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pediatrneurol.2015.05.004","article-title":"Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin on immediate and continued spasm control in West syndrome","volume":"53","author":"Wanigasinghe","year":"2015","journal-title":"Pediatr Neurol"},{"key":"2025030420305202000_fmaf005-B8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2352-4642(18)30244-X","article-title":"Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial","volume":"2","author":"O'Callaghan","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2025030420305202000_fmaf005-B9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.yebeh.2009.01.023","article-title":"High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH","volume":"14","author":"Kossoff","year":"2009","journal-title":"Epilepsy Behav"},{"key":"2025030420305202000_fmaf005-B10","doi-asserted-by":"crossref","first-page":"756746","DOI":"10.3389\/fneur.2021.756746","article-title":"Safety and effectiveness of oral methylprednisolone therapy in comparison with intramuscular adrenocorticotropic hormone and oral prednisolone in children with infantile spasms","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Neurol"},{"key":"2025030420305202000_fmaf005-B11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pediatrneurol.2019.06.012","article-title":"Very-high-dose prednisolone before ACTH for treatment of infantile spasms: evaluation of a standardized protocol","volume":"99","author":"Eliyan","year":"2019","journal-title":"Pediatr Neurol"},{"key":"2025030420305202000_fmaf005-B12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.seizure.2013.04.014","article-title":"Clinical spectrum and treatment outcome of West syndrome in children from Northern India","volume":"22","author":"Kaushik","year":"2013","journal-title":"Seizure"},{"key":"2025030420305202000_fmaf005-B13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0387-7604(01)00288-1","article-title":"West syndrome and other infantile epileptic encephalopathies\u2014Indian hospital experience","volume":"23","author":"Kalra","year":"2001","journal-title":"Brain Dev"},{"key":"2025030420305202000_fmaf005-B14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0387-7604(01)00267-4","article-title":"Epidemiological and clinical studies of West syndrome in Nagasaki Prefecture, Japan","volume":"23","author":"Matsuo","year":"2001","journal-title":"Brain Dev"},{"key":"2025030420305202000_fmaf005-B15","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1528-1167.2010.02695.x","article-title":"The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification","volume":"51","author":"Osborne","year":"2010","journal-title":"Epilepsia"},{"key":"2025030420305202000_fmaf005-B16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1528-1157.1999.tb00773.x","article-title":"The descriptive epidemiology of infantile spasms among Atlanta children","volume":"40","author":"Trevathan","year":"1999","journal-title":"Epilepsia"},{"key":"2025030420305202000_fmaf005-B17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fneur.2012.00166","article-title":"West syndrome: response to valproate","volume":"3","author":"Chandra","year":"2012","journal-title":"Front Neurol"}],"container-title":["Journal of Tropical Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/71\/2\/fmaf005\/61904043\/fmaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/71\/2\/fmaf005\/61904043\/fmaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:36:45Z","timestamp":1741124205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tropej\/article\/doi\/10.1093\/tropej\/fmaf005\/8016209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/tropej\/fmaf005","relation":{},"ISSN":["1465-3664"],"issn-type":[{"value":"1465-3664","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,5]]},"article-number":"fmaf005"}}